In line with its essential role in programmed necrosis, pharmacological inhibition of RIPK1 by necrostatin-1 protected the same subset of sensitive tumor cell lines that we had used for analysis in Figure 1d (resistant KNS-62 cells were again included as control) from both TRAIL/zVAD/CHX- and TNF/zVAD/CHX-induced programmed necrosis (Figure 3a). The gene discussed is RIPK1; the disease is neoplasm.